学习与工作经历：

2002.09-2007.06   山东大学 血液专业硕博连读

2007.08-至今      山东大学齐鲁医院 小儿内科

2011.12-2015.06   山东大学基础医学院  免疫学博士后

2018.08-2019.08   哈佛大学波士顿儿童医院 高级访问学者

2020.11-至今      山东大学齐鲁医院    小儿内科副主任

2022.06-至今      山东大学齐鲁医学院  儿科学系 常务副主任

2023.01-至今      山东大学齐鲁医院    儿科教研室主任

研究方向：

擅长儿童血液系统疾病及实体肿瘤的临床诊治及机制研究。

学术/社会兼职：

中华医学会儿科分会          青年委员

中华医学会儿科分会血液学组  青年委员

山东省医学会儿科分会        青委会副组长

山东省研究型医院儿童血液肿瘤分会  主任委员

山东省伦理学会小儿内科分会        主任委员

山东省抗癌学会儿科分会      副主任委员

山东大学齐鲁医学院名医体系  杰出青年医师

获奖荣誉：

2016 山东大学齐鲁医院第三届“青年杰出人才”

2018 山东大学齐鲁医学院名医体系“杰出青年医师” 

2016 住院医师规范化培训“优秀指导老师”

2016 美国AHA认证PALS/BLS导师

2018 山东大学“医学生喜爱的带教老师”

2022 住院医师规范化培训“十佳指导老师”

2022 齐鲁医院“医院先进工作者”

2023 山东大学“齐鲁医学优秀教师”

本科生课程：

儿科学

研究生课程：

儿科学

1. ZR202010220039  肠道菌群调控药物基因多态性相关HD-MTX化疗后粘膜损伤的作用机制研究  山东省自然基金重点支持项目  2021.01-2023.12  25万  项目负责人（第一位）

2. 2019GSF108060  HAT/HDAC平衡失调对儿童难治性ITP中Treg/Th17细胞异常的作用机制研究  山东省重点研发计划  2019.01-2020.12  15万  项目负责人（第一位）

3. 30801258  GFP来源抗原特异性未成熟树突状细胞诱导FcRIIA转基因ITP小鼠免疫耐受的实验研究  国家自然科学基金  2009.1-2011.12  20万  项目负责人（第一位）

4. ZR2014HM093  GPIIIa脉冲刺激特异性诱导耐受态DC靶向治疗儿童ITP的机制研究  山东省自然基金面上项目  2015.01-2017.12  13万  项目负责人（第一位）

5. 2013T6675  GPIb脉冲刺激特异性诱导耐受态DC靶向治疗儿童ITP  教育部博士后特别资助  2013.01-2014.12  15万  项目负责人（第一位）

6. 2013021  microRNA155在ITP儿童Th17/Treg平衡失调中的调控作用  济南市科技明星计划  2013.07-2015.07  6万  项目负责人（第一位）

7. 2012M511036  microRNA155在难治性ITP儿童Th17/Treg平衡失调中的调控作用  2012.01-2013.12  5万  项目负责人（第一位）

8. 81070407  Notch通路在ITP患者Th17/Treg平衡失调中的作用及机制研究  国家自然科学基金  2011.1-2013.12  32万  项目负责人（参与）

9. 81100336  新共刺激分子ICOS及ICOS-Ig诱导T细胞免疫耐受在再生障碍性贫血中的研究  国家自然科学基金  2012.1-2014.12  20万  项目负责人（参与）

10. 81070411  树突状细胞中KLF10在特发性血小板减少性紫癜免疫耐受中的作用及机制研究  国家自然科学基金  2011.1-2013.12  35万  项目负责人（参与）

11. 30770922  TLR7/BlyS/TRAFs信号传导途径在ITP发病中的分子机制研究  国家自然科学基金  2008.1-2010.12  32万  项目负责人（参与）

1.Zhou Y, He H, Ding L, Wang T, Liu X, Zhang M,Zhang A. Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia. European Journal of Pediatrics. 2023. Epub.

2.Liu K, Shao J, Cai J, Tang J, Shen S, Xu F, Ren Y,Zhang A, Tian X, Lu X, Hu S, Hu Q, Jiang H, Zhou F, Liang C, Leung AWK, Li C, Fang Y, Wang Z, Wen L, Yang H, Wang N, Jiang H. Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children's Cancer Group study ALL-2015. Ann Hematol. 2023 Aug 8.

3.Shen L, Li H, Liu R, Zhou C, Bretches M, Gong X, Lu L, Zhang Y, Zhao K, Ning B, Yang SY,Zhang A. DEPDC1 as a crucial factor in the progression of human osteosarcoma. Cancer Med. 2023 Mar;12(5):5798-5808.

4.Li T, Liu Q, Pu T, Liu J,Zhang A. Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis. Expert Opin Pharmacother. 2023 Apr;24(6):763-774.

5.Liu Q, Fu J,Zhang A. Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review. Transl Cancer Res. 2023 Jan 30;12(1):194-200.

6.Fu J,Zhang A, Liu Q, Li D, Wang X, Si L. Metabolic profiling reveals metabolic features of consolidation therapy in pediatric acute lymphoblastic leukemia. Cancer Metab. 2023 Jan 23;11(1):2.

7.Zhou Y, Zhou C,Zhang A. Gut microbiota in acute leukemia: Current evidence and future directions. Front Microbiol. 2022 Dec 1;13:1045497.

8.Zhang Y, Liu J, Chen J, Zhang W, Wu J, Yue T,Zhang A. Entrustable Professional Activities for Chinese Standardized Residency Training in Pediatric Intensive Care Medicine. Front Pediatr. 2022 Jul 4;10:919481.

9.Hu Y, Zhang X,Zhang A, Hou Y, Liu Y, Li Q, Wang Y, Yu Y, Hou M, Peng J, Yang X, Xu S. Global burden and attributable risk factors of acute lymphoblastic leukemia in 204 countries and territories in 1990-2019: Estimation based on Global Burden of Disease Study 2019. Hematol Oncol. 2022 Feb;40(1):92-104.

10.Li M, Wang X, Lin X, Bian X, Jing R, Frelinger A,Zhang A. Comparison and Analysis of Gut Microbiota in Children With IgA Vasculitis With Different Clinical Symptoms. Front Pediatr. 2022 Jan 7;9:800677.

11.Mazzeffi M, Tanaka K, Wu YF,Zhang A, Kareddy N, Tadjou Tito E, Rock P, Michelson AD, Frelinger AL. Platelet surface GPIbα, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients. Platelets. 2022 Jan 2;33(1):116-122.

12.Zhou C, Zhuang Y, Lin X, Michelson AD,Zhang A. Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis. Br J Haematol. 2020 Mar;188(6):945-961.

13.Shen L, Zhao K, Li H, Ning B, Wang W, Liu R, Zhang Y,Zhang A. Downregulation of UBE2T can enhance the radiosensitivity of osteosarcoma in vitro and in vivo. Epigenomics. 2019 Aug;11(11):1283-1305.

14.Shao K, Wang T, Li T,Zhang A, Cai M, Zhao G, Fu Q, Wang Q, Liu X, Hou M. Indirubin regulates MPL and TNF expression in peripheral blood mononuclear cells from patients with primary immune thrombocytopenia. Exp Hematol. 2019 May;73:18-24.

15.Fu J, Si L, Zhuang Y,Zhang A, Sun N, Li D, Hao B, Ju X. Wnt/βcatenin inhibition reverses multidrug resistance in pediatric acute lymphoblastic leukemia. Oncol Rep. 2019 Feb;41(2):1387-1394.

16.Li M, Bian X, Jing R,Zhang A, Sun N, Ju X, Li F. Retrospective analysis of rhabdomyosarcoma (RMS) in children in a single center. Thorac Cancer. 2018 Sep;9(9):1180-1184.

17.Zhang A, Ning B, Sun N, Wei J, Ju X. Indirubin Increases CD4+CD25+Foxp3+ Regulatory T Cells to Prevent Immune Thrombocytopenia in Mice. PLoS One. 2015 Nov 16;10(11):e0142634.

18.Ning B, Wei J,Zhang A, Gong W, Fu J, Jia T, Yang SY. Antigen-specific tolerogenic dendritic cells ameliorate the severity of murine collagen-induced arthritis. PLoS One. 2015 Jun 24;10(6):e0131152.

19.Zhang A, Fu J, Ning B, Li D, Sun N, Wei W, Wei J, Ju X. Tolerogenic dendritic cells generated with IL-10/TGFβ1 relieve immune thrombocytopenia in mice. Thromb Res. 2013 Jul;132(1):63-8.

20.Fu J,Zhang A, Ju X. Tolerogenic dendritic cells as a target for the therapy of immune thrombocytopenia. Clin Appl Thromb Hemost. 2012 Sep;18(5):469-75.

21.Zhao Y,Zhang A, Du H, Guo S, Ning B, Yang S. Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives. Rheumatol Int. 2012 Apr;32(4):837-44.

22.Ning B,Zhang A, Song H, Gong W, Ding Y, Guo S, Zhao Y, Jiang J, Jia T. Recombinant human erythropoietin prevents motor neuron apoptosis in a rat model of cervical sub-acute spinal cord compression. Neurosci Lett. 2011 Feb 18;490(1):57-62.

23.Qu Y, Zhang B, Liu S,Zhang A, Wu T, Zhao Y. 2-Gy whole-body irradiation significantly alters the balance of CD4+ CD25- T effector cells and CD4+ CD25+ Foxp3+ T regulatory cells in mice. Cell Mol Immunol. 2010 Nov;7(6):419-27.

24.Qu Y, Jin S,Zhang A, Zhang B, Shi X, Wang J, Zhao Y. Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice. Radiat Res. 2010 Feb;173(2):148-57.

25.Javeed A, Zhang B, Qu Y,Zhang A, Sun C, Zhang L, Liu J, Zeng C, Zhao Y. The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice. Transpl Immunol. 2009 Mar;20(4):253-60.

26.Zhang B,Zhang A, Qu Y, Liu J, Niu Z, Zhao Y. Development of mouse CD4(+)CD25(+)Foxp3(+) regulatory T cells in xenogeneic pig thymic grafts. Transpl Immunol. 2009 Jan;20(3):180-5.

27.Zhang B,Zhang A, Zhao Y. Platelet aggregation and thrombosis in xenotransplantation between pigs and humans. Thromb Res. 2008;121(4):433-41.

28.Zhang B, Sun C, Qu Y,Zhang A, Liu J, Zhang L, Niu Z, Zhao Y. Deficiency of mouse CD4+CD25+Foxp3+ regulatory T cells in xenogeneic pig thymus-grafted nude mice suffering from autoimmune diseases. Cell Mol Immunol. 2008 Oct;5(5):325-32.

29.Zhang A, Qu Y, Zhang B, Zhang L, Zeng C, Peng J, Ji X, Hou M, Zhao Y. The different effects of indirubin on effector and CD4+CD25+ regulatory T cells in mice: potential implication for the treatment of autoimmune diseases. J Mol Med (Berl). 2007 Nov;85(11):1263-70.

30.Zhang A, Hou M .Progress of studies on animal model of immune thrombocytopenic purpura--review.Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Jun;14(3):623-6.

31.张爱军,刘芹芹,浦婷.儿童免疫性血小板减少症的规范治疗与管理.临床儿科杂志,2022,40(02):81-86.

32.张爱军,侯明,孙念政等.靛玉红诱导免疫性血小板减少性紫癜小鼠免疫耐受机制的研究.山东大学学报(医学版),2010,48(12):42-45+50.

33.张爱军,侯明.血浆置换在血小板减少症中的应用.血栓与止血学,2005(04):183-185.